Corporate Social Responsibility in Countries with Mature and Emerging Pharmaceutical
Main Article Content
Keywords
Drug Industry, Social Responsibility, Russia, Germany
Abstract
In recent decades the concept of Corporate Social Responsibility (CSR) has been adopted by many business sectors, including the pharmaceutical industry. However, in this and other sectors its application remains variable, particularly between mature and developing economies. Its stakeholders include pharmacy and medical students, their attitude to the involvement of companies in socially responsible activities will be important determinants of public response to the industry.
Objective: To investigate the knowledge, attitudes and practices of senior medical and pharmacy students towards the CSR concept in the pharmaceutical sector in mature (Germany) and developing (Russia) markets.
Methods: A questionnaire survey was carried out among senior pharmacy and medical students during the summer semester 2008 in two Russian and one German university. In each country 120 questionnaires were distributed. The response rate was 95% in Russia and 93% in Germany.
Results: Although the relevance of CSR was widely acknowledged by the students, very few were aware of CSR practices currently performed by companies. The reputation of the pharmaceutical industry was generally poor: less than 15% of respondents gave credence to the information provided in advertisements and fully supported pricing strategies as well as policies towards the developing countries. When choosing an employer more than 90% of respondents consider the policies affecting an employee directly as pivotal. However, for a high proportion of students (59% in Russia and 64% in Germany) socially irresponsible behavior by companies has a significant negative impact.
Conclusions: This paper identifies practices which students believe should be a part of the CSR programmes for the pharmaceutical industry, and also some that should be abandoned. It recommends that corporate communication on CSR should be expanded. Key differences are seen in perceptions of students in Germany and Russia towards the extent of irresponsible actions and the variation between them.
References
2. Kilcullen M, Kolstra JO. At least do no harm: sources on the changing role of business ethics and corporate social responsibility. Ref Serv Rev. 1999;27(2):158.
3. Maignan I, Ferrell OC. Corporate social responsibility and marketing: an integrative framework. J Acad Mark Sci. 2006;34(2):158-166.
4. Palazzo G, Richter U. CSR business as usual? The case of the tobacco industry. J Business Ethics. 2005;61:387-401.
5. Hirschhorn N. Corporate Social responsibility and the tobacco industry: hope or hype? Tobacco Contr. 2004;13:447-453.
6. Barraclough S, Morrow M. A grim contradiction: the practice and consequences of corporate social responsibility by British American Tobacco in Malaysia. Soc Sci Med. 2008;66 (8):1784-1796.
7. Givel M. Motivation of chemical industry corporate social responsibility through responsible care. Health Policy. 2007;81:85-92.
8. Dukes MNG. The law and ethics of the pharmaceutical industry. 2nd ed. London: Elsevier; c2005. Chapter 2.10: Corporate social responsibility and governments. pp. 109-123.
9. Esteban, D. Strengthening Corporate Social Responsibility in the Pharmaceutical Industry. J Med Mark. 2008;8(4):77-79.
10. Weyzig, F. (2004) Sector profile of the Pharmaceutical Industry. Amsterdam: Somo.
11. Single Market News (2000) The Lisbon Summit: Concrete Action to Stimulate European Competitiveness. Available at: http://ec.europa.eu/internal_market/smn/smn21/s21mn14.htm (Accessed: 19 May 2008).
12 European Union Green Paper (2002) Promoting a European Framework for Corporate Social Responsibility. Available at: http://www.jussemper.org/Resources/Corporate%20Activity/Resources/greenpaper_en.pdf (Accessed: 15 April 2008).
13. European Union White Paper (2002) Communication concerning Corporate Social Responsibility: A Business Contribution to Sustainable Development. Available at: http://www.jussemper.org/Resources/Corporate%20Activity/Resources/sipade2.pdf (Accessed: 17 April 2008).
14. Mshvelidse, E. Investment in the Future. Pharm Rep. 2006;21(426):13-15.
15. Pharmacy reporter. Philanthropy in the pharmaceutical market. Pharm Rep. 2006a;21(4):29-30.
16. Pharmacy reporter. Corporate Social Responsibility: what needs to be discussed. Pharm Rep. 2006b;11(62):2-4.
17. Latif DA, Berger BA. Moral reasoning in pharmacy students and community practitioners. J Soc Admin Pharm.. 1997;14(3):166-179.
18. Anderson SC, Huss R, Summers R, Wiedenmayer K. Managing Pharmaceuticals in International Health. 2nd ed. Basel, Switzerland: Birkhauser; c2005. Chapter 4, Managing Pharmaceuticals in International Health: Policy Initiatives and their Implications; p. 156-169. Available at: http://www.hillandknowlton.com/press/releases/2008/01/16/global-study-of-elite-mba-students (Accessed: 5 June 2008).
19. Freeman R, Liedtka, J. Corporate Social Responsibility: a Critical Approach. Business Horizons. 1991;34(4): 92-98.
20. United Nations Industrial Development Organization (UNIDO). Building linkages for Competitive and Responsible Entrepreneurship. [Internet]. 2007 [cited 2008 April 8] Available at: http://www.unido.org/fileadmin/import/69447_CSRI_08.pdf
21. European Union White Paper. Communication concerning Corporate Social Responsibility: A Business Contribution to Sustainable Development. [Internet]. 2002 [cited 2008 April 17] Available at: http://www.jussemper.org/Resources/Corporate%20Activity/Resources/sipade2.pdf
22. Leisinger, K. Corporate Responsibility for Access to Medicines. Journal for Business Ethics; Feb 2009;85 (1):3-23.
23. European Union Green Paper. Promoting a European Framework for Corporate Social Responsibility. . [Internet]. 2002 [cited 2008 April 15] Available at: http://www.jussemper.org/Resources/Corporate%20Activity/Resources/greenpaper_en.pdf
24. Karima R, Oshima Y, Yamamoto K. Identification of subjects for Social Responsibility Education at Universities and the present activity of the University of Tokyo. Environ Sci.. 2006; 13 (6):327-337.
25. Dukes G. Accountability of the pharmaceutical industry. Lancet.. 2002;360 (1):1682-1684.
26. Nissan, S. A Bitter Pill to Swallow? [date, publisher unknown]. Internet. [cited 2008 May 17] Available at: http://www.innovestgroup.com/pdfs/2003-08-28bitter_pill.pdf
27. PricewaterhouseCoopers’ Health Research Institute (2005) Recapturing the vision: Integrity driven performance in the pharmaceutical industry. London: PricewaterhouseCoopers LLP.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.